Daïen C - Search Results

1

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.

Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B. Lukas C, et al. Among authors: daien c. Arthritis Res Ther. 2019 Nov 15;21(1):243. doi: 10.1186/s13075-019-2020-x. Arthritis Res Ther. 2019. PMID: 31730497 Free PMC article. Clinical Trial.

2

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.

Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J; Club Rhumatismes et Inflammation (CRI). Daïen CI, et al. Rheumatology (Oxford). 2009 Aug;48(8):883-6. doi: 10.1093/rheumatology/kep046. Epub 2009 May 7. Rheumatology (Oxford). 2009. PMID: 19423648 Review.

3

[Rheumatoid arthritis: a cardiovascular disease?].

Daïen CI, Fesler P. Daïen CI, et al. Ann Cardiol Angeiol (Paris). 2012 Apr;61(2):111-7. doi: 10.1016/j.ancard.2011.07.008. Epub 2011 Aug 17. Ann Cardiol Angeiol (Paris). 2012. PMID: 21885031 Review. French.

4

Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis.

Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Daïen CI, et al. Ann Rheum Dis. 2012 Jun;71(6):862-8. doi: 10.1136/annrheumdis-2011-201148. Epub 2012 Jan 20. Ann Rheum Dis. 2012. PMID: 22267329 Review.

5

Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study.

Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, Morel J. Daïen CI, et al. J Rheumatol. 2012 Aug;39(8):1533-8. doi: 10.3899/jrheum.111522. Epub 2012 Jul 1. J Rheumatol. 2012. PMID: 22753654

6

Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.

Daïen CI, Fesler P, du Cailar G, Daïen V, Mura T, Dupuy AM, Cristol JP, Ribstein J, Combe B, Morel J. Daïen CI, et al. Ann Rheum Dis. 2013 Jun;72(6):881-7. doi: 10.1136/annrheumdis-2012-201489. Epub 2012 Aug 7. Ann Rheum Dis. 2013. PMID: 22872022 Clinical Trial.

7

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Daïen CI, Morel J. Daïen CI, et al. Mediators Inflamm. 2014;2014:386148. doi: 10.1155/2014/386148. Epub 2014 Jan 12. Mediators Inflamm. 2014. PMID: 24523570 Free PMC article. Review.

8

Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity.

Daien CI, Gailhac S, Mura T, Audo R, Combe B, Hahne M, Morel J. Daien CI, et al. Arthritis Rheumatol. 2014 Aug;66(8):2037-46. doi: 10.1002/art.38666. Arthritis Rheumatol. 2014. PMID: 24729478

9

High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study.

Daien CI, Gailhac S, Mura T, Combe B, Hahne M, Morel J. Daien CI, et al. Arthritis Res Ther. 2014 Apr 15;16(2):R95. doi: 10.1186/ar4543. Arthritis Res Ther. 2014. PMID: 24735586 Free PMC article.

10

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J. Daïen CI, et al. Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16. Rheumatology (Oxford). 2015. PMID: 25231180 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page